On 12 AUG Array BioPharma, Inc. (NASDAQ:ARRY) announced its earnings results on Tuesday. The company reported ($0.22) earnings per share for the quarter, beating the analysts' consensus estimate of ($0.23) by $0.01.
Key candidates in Array BioPharma's pipeline include filanesib, selumetinib and binimetinib. Array BioPharma expects Novartis, which currently owns the development and commercialization rights to binimetinib, to return the same.
Las Vegas, NV - 13 August, 2014� (TechSonian) - Array Biopharma Inc (NASDAQ:ARRY) reported financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014.